Skip to main navigation Skip to search Skip to main content

Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin

  • Mario A. Shields
  • , Christina Spaulding
  • , Anastasia E. Metropulos
  • , Mahmoud G. Khalafalla
  • , Thao N.D. Pham
  • , Hidayatullah G. Munshi
  • Northwestern University
  • Department of Veterans Affairs

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Gα13 transduces signals from G-protein-coupled receptors. While Gα13 functions as a tumor suppressor in lymphomas, it is not known whether Gα13 is pro-tumorigenic or tumor suppressive in genetically engineered mouse (GEM) models of epithelial cancers. Here, we show that loss of Gα13 in the Kras/Tp53 (KPC) GEM model promotes well-differentiated tumors and reduces survival. Mechanistically, tumors developing in KPC mice with Gα13 loss exhibit increased E-cadherin expression and mTOR signaling. Importantly, human pancreatic ductal adenocarcinoma (PDAC) tumors with low Gα13 expression also exhibit increased E-cadherin expression and mTOR signaling. Treatment with the mTOR inhibitor rapamycin decreases the growth of syngeneic KPC tumors with Gα13 loss by promoting cell death. This work establishes a tumor-suppressive role of Gα13 in pancreatic tumorigenesis in the KPC GEM model and suggests targeting mTOR in human PDAC tumors with Gα13 loss.

Original languageEnglish
Article number110441
JournalCell Reports
Volume38
Issue number9
DOIs
StatePublished - Mar 1 2022

Keywords

  • E-cadherin
  • Gα13
  • human PDAC tumors
  • KC mouse model
  • KPC mouse model
  • mTOR
  • rapamycin

Fingerprint

Dive into the research topics of 'Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin'. Together they form a unique fingerprint.

Cite this